PDGFRB and neoplasm: As a novel multi‐target TKI developed independently in China, anlotinib has shown in vitro and in vivo antitumor effect on several types of tumor models by blocking vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet‐derived growth factor receptors (PDGFR), c‐Kit, and Ret simultaneously, and has a broad‐spectrum involvement in tumorigenesis and tumor angiogenesis.11